Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Planning for the future: "We already have several manufacturing lines built for the new device and testing cups and have recently signed a new lease to add to our production capacity. Headcount has grown over 66% compared to prior year quarter. Our investments in talent and R&D remain positive indicators of the progress we are achieving to drive further value for our shareholders. This is facilitated by our strong cash position that reflects our success to this point, and provides the necessary flexibility as we remain in the forefront of the challenging diagnostic landscape."
Opti
With the projected global addressable TB market of $3.13 billion, I would love to see a future PR at the time of the relaease of one of the grants to emphasize that CODX is aggressively pursuing that market. $$$$ earnings in the future.
Opti
And more from Dwight: "The global addressable TB diagnostics market is expected to grow from 2.07 billion in 2022 to 3.13 billion by 2029. We believe the interest among NGOs and our new platform partially reflects their refocus on eradicating TB. We regard these grants as being in lockstep with the natural evolution of our vision and strategic plan. The company’s first CE marking received 5 years ago this July was for our Logix Smart MTB test built using our CoPrimer’s technology. The difference between then and now is we have grown beyond mere aspirations and now find ourselves fully in execution mode. With internationally recognized technology, world renowned experts and a point-of-care platform different from anything the world has ever seen, I want to emphasize that our new platform has been designed and engineered to be versatile and durable, with long-term disruptive potential as a diagnostic medical device. Harnessing the power of our patented battle tested CoPrimer’s technology coupled with other proprietary IP, we believe this platform sets a new benchmark for compact point-of-care testing that unlocks the multiplexing potential of real-time PCR."
Opti
Further comments by Dwight: "Other grants relate to a tuberculosis product being designed and verified on the Co-Dx PCR Home platform in preparation for validation and clinical trials. Tuberculosis abbreviated MTB or just TB has been highly endemic in certain geographic regions for generations. And despite all advances in modern medicine still took the lives of 1.6 million people in 2021. Some of the uptick in TB incidences and death since 2020 may be the result of funding that might otherwise have been allocated to TB being re-appropriated to COVID-related concerns. This has created an urgency among NGOs to slow the spread of the disease to increase access to gold standard real-time diagnostics, exactly in line with our mission and our new platform."
Opti
Dwight at the earnings call "Recently, we were notified that we had been selected to receive multiple grants for our respiratory multiplex and tuberculosis tests on our new platform. While we are unable to announce the details of these grants, we believe the recognition from these prominent organizations is a testament to the platform technology we are bringing to market, including the new device and our patented CoPrimer technology. One grant is related to the ABC plus RSV respiratory panel on the Co-Dx PCR Home platform as well as additional platform enhancements and was a monumental task that involved a thorough investigation by industry experts into every aspect of the platform. It’s design, history, the chemistry of the reagents, and the individuals responsible with making our vision a reality."
Opti
May 11 short volumes: CODX 53%, FLGT 52%, HLTH 52%, QDEL 81%, VERU 63%.
May 10 short volumes: CODX 28%, FLGT 36%, HLTH 50%, QDEL 65%, VERU 62%.
May 9 short volumes: CODX 16%, FLGT 45%, HLTH 61%, QDEL 71%, VERU 69%.
May 8 short volumes: CODX 22%, FLGT 35%, HLTH 72%, QDEL 72%, VERU 70%.
May 5 short volumes: CODX 28%, FLGT 25%, HLTH 50%, QDEL 72%, VERU 57%.
May 4 short volumes: CODX 42%, FLGT 65%, HLTH 75%, QDEL 83%, VERU 58%.
May 3 short volumes: CODX 24%, FLGT 54%, HLTH 69%, QDEL 58%, VERU 66%.
May 2 short volumes: CODX 43%, FLGT 46%, HLTH 67%, QDEL 78%, VERU 60%.
May 1 short volumes: CODX 47%, FLGT 46%, HLTH 74%, QDEL 70%, VERU 53%.
Apr 28 short volumes: CODX 26%, FLGT 50%, HLTH 69%, QDEL 62%, VERU 50%.
Apr 27 short volumes: CODX 38%, FLGT 49%, HLTH 68%, QDEL 75%, VERU 44%.
Apr 26 short volumes: CODX 25%, FLGT 53%, HLTH 75%, QDEL 80%, VERU 42%.
Apr 25 short volumes: CODX 23%, FLGT 53%, HLTH 62%, QDEL 82%, VERU 41%.
Apr 24 short volumes: CODX 17%, FLGT 44%, HLTH 60%, QDEL 70%, VERU 60%.
Apr 21 short volumes: CODX 31%, FLGT 52%, HLTH 60%, QDEL 61%, VERU 61%.
Apr 20 short volumes: CODX 38%, FLGT 43%, HLTH 47%, QDEL 64%, VERU 59%.
Apr 19 short volumes: CODX 11%, FLGT 55%, HLTH 34%, QDEL 56%, VERU 53%.
Apr 18 short volumes: CODX 27%, FLGT 42%, HLTH 61%, QDEL 61%, VERU 51%.
Apr 17 short volumes: CODX 27%, FLGT 33%, HLTH 55%, QDEL 66%, VERU 50%.
Apr 14 short volumes: CODX 44%, FLGT 51%, HLTH 76%, QDEL 70%, VERU 57%.
Apr 13 short volumes: CODX 35%, FLGT 49%, HLTH 52%, QDEL 59%, VERU 47%.
Apr 12 short volumes: CODX 40%, FLGT 44%, HLTH 63%, QDEL 65%, VERU 55%.
Apr 11 short volumes: CODX 31%, FLGT 39%, HLTH 41%, QDEL 60%, VERU 48%.
Apr 10 short volumes: CODX 18%, FLGT 34%, HLTH 58%, QDEL 40%, VERU 34%.
Apr 6 short volumes: CODX 23%, FLGT 33%, HLTH 42%, QDEL 32%, VERU 52%.
Apr 5 short volumes: CODX 28%, FLGT 56%, HLTH 79%, QDEL 69%, VERU 70%.
Apr 4 short volumes: CODX 28%, FLGT 48%, HLTH 55%, QDEL 61%, VERU 78%.
Apr 3 short volumes: CODX 21%, FLGT 41%, HLTH 73%, QDEL 63%, VERU 72%.
Mar 31 short volumes: CODX 27%, FLGT 53%, HLTH 31%, QDEL 62%, VERU 70%.
Mar 30 short volumes: CODX 36%, FLGT 44%, HLTH 43%, QDEL 60%, VERU 71%.
Mar 29 short volumes: CODX 29%, FLGT 60%, HLTH 62%, QDEL 61%, VERU 60%.
Mar 28 short volumes: CODX 29%, FLGT 59%, HLTH 59%, QDEL 65%, VERU 66%.
Mar 27 short volumes: CODX 37%, FLGT 53%, HLTH 32%, QDEL 75%, VERU 53%.
Mar 24 short volumes: CODX 33%, FLGT 44%, HLTH 36%, QDEL 66%, VERU 58%.
Mar 23 short volumes: CODX 27%, FLGT 45%, HLTH 52%, QDEL 64%, VERU 47%.
Mar 22 short volumes: CODX 28%, FLGT 42%, HLTH 67%, QDEL 48%, VERU 48%.
Mar 21 short volumes: CODX 23%, FLGT 66%, HLTH 53%, QDEL 26%, VERU 63%.
Mar 20 short volumes: CODX 25%, FLGT 50%, HLTH 38%, QDEL 60%, VERU 51%.
Mar 17 short volumes: CODX 21%, FLGT 65%, HLTH 60%, QDEL 60%, VERU 52%.
Mar 16 short volumes: CODX 23%, FLGT 55%, HLTH 54%, QDEL 52%, VERU 60%.
Earnings today after the close.
Opti
Mar 15 short volumes: CODX 41%, FLGT 51%, HLTH 64%, QDEL 52%, VERU 53%.
Mar 14 short volumes: CODX 38%, FLGT 54%, HLTH 66%, QDEL 68%, VERU 42%.
Mar 13 short volumes: CODX 33%, FLGT 64%, HLTH 52%, QDEL 66%, VERU 48%.
Followers
|
86
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3996
|
Created
|
09/15/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |